1、1Third Quarter 2025Earnings TeleconferenceNovember4,2025Third Quarter 2025 Earnings2IntroductionFrancesca DeMartinoChief Investor Relations Officer,Senior Vice PresidentThird Quarter 2025 Earnings3 Our discussions during this conference call will include forward-looking statements that are subject t

2、o substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements.We include forward-looking statements about,among other topics,our anticipated operating and financial performance,including financial guidance and projection

3、s;changes to Pfizers R&D and commercial organizations;reorganizations;business plans,strategy,goals and prospects;expectations for our product pipeline(including products from completed or anticipated acquisitions),in-line products and product candidates,including anticipated regulatory submissions,

4、data read-outs,study starts,approvals,launches,discontinuations,clinical trial results and other developing data,revenue contribution and projections,potential pricing and reimbursement,potential market dynamics,including demand,market size and utilization rates and growth,performance,timing of excl

5、usivity and potential benefits;the impact and potential impact of tariffs and pricing dynamics;strategic reviews;leverage and capital allocation objectives;an enterprise-wide cost realignment program(including anticipated costs,savings and potential benefits);a manufacturing optimization program to

6、reduce our cost of goods sold(including anticipated costs,savings and potential benefits);dividends and share repurchases;plans for and prospects of our acquisitions,dispositions and other business development activities,including our acquisition of Seagen,our proposed acquisition of Metsera and our